Phase 2 Leukaemia Trial, Recruiting NCT07493538 Sponsor: Masonic Cancer Center, University of Minnesota Condition: Leukaemia
Back to Leukaemia

Phase 2 Leukaemia Trial, Recruiting

NCT07493538
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between 2 and 75 years of age
  • People who have a reasonable level of physical functioning, measured by a standard performance score (Karnofsky score of 70% or above for those aged 16 and older, or Lansky play score of 50 or above for those under 16) (confirm with trial site)
  • People who have a suitable bone marrow or stem cell donor — this includes a related donor who matches on 5 or 6 out of 6 markers, an unrelated donor who matches on 5 to 8 out of 8 specific genetic markers, or a related donor who matches on at least 5 out of 10 markers
  • People whose liver is functioning well enough, with no severe liver failure and certain blood test results within acceptable ranges (confirm with trial site)
  • People whose kidneys are functioning well enough, based on a standard blood test result below a set level (confirm with trial site)
  • People whose heart is functioning adequately, with no severe heart failure or uncontrolled irregular heartbeat, and a heart pumping strength of at least 40%
  • People whose lungs are functioning adequately, with breathing test results at 40% or above of the expected level and no need for supplemental oxygen

Who may not be able to join:

  • People who are pregnant or breastfeeding
  • People with an HIV infection that has not been treated or is not under control
  • People with a serious active infection that has not been treated or is not under control
  • People with cancer that is actively affecting the brain or central nervous system
  • People with a specific type of leukemia (CML) that has progressed to a severe stage called blast crisis and has not reached a remission with normal blast cell counts
  • People who have had a high-intensity (myeloablative) stem cell transplant within the past 3 months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 612-625-3051

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Masonic Cancer Center, University of Minnesota
Registry
ClinicalTrials.gov
Start date
10 April 2026
Est. completion
1 March 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Overall Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov